# **Complete Summary**

#### **TITLE**

Bipolar disorder: the percentage of patients diagnosed and treated for bipolar disorder who are monitored for change in their symptom complex within 12 weeks of initiating treatment.

# SOURCE(S)

STABLE (STAndards for BipoLar Excellence) performance measures. Boston (MA): Center for Quality Assessment and Improvement in Mental Health; 2007. various p.

## **Measure Domain**

#### **PRIMARY MEASURE DOMAIN**

**Process** 

The validity of measures depends on how they are built. By examining the key building blocks of a measure, you can assess its validity for your purpose. For more information, visit the Measure Validity page.

## **SECONDARY MEASURE DOMAIN**

Does not apply to this measure

## **Brief Abstract**

## **DESCRIPTION**

This measure is used to assess the percentage of patients diagnosed and treated for bipolar disorder who are monitored for change in their symptom complex within 12 weeks of initiating treatment.

#### **RATIONALE**

### **Acute Treatment Phase and Remission**

- Recovery includes remission of symptomatology, functional recovery, prevention of relapse or recurrence and improved quality of life.
- The 2002 American Psychiatric Association (APA) Practice Guideline for the Treatment of Patients with Bipolar Disorder states that the goal of acute treatment is stabilization of the episode with the goal of remission, defined as

"a complete return to baseline level of functioning and a virtual lack of symptoms".

# **Bipolar Disorder and Response to Treatment**

- The mood episodes of bipolar disorder are delineated in Diagnostic and Statistical Manual of Mental Disorders, Fourth Revision (DSM-IV) by symptomatology; therefore, diagnosing and assessing response to treatment involves symptom monitoring.
- As defined by Tohen improvement in bipolar disorder involves two concepts involving symptoms; syndromal recovery, a sustained symptomatic recovery lasting for 8 weeks and symptomatic remission, a more stringent concept that is defined as a more symptom-free state.

## **Monitoring Symptomatology**

- Recognizing and monitoring signs and symptoms of manic and depressive symptoms is critical in assessing patient status.
- The use of a graphic display or timeline of mood symptoms can be helpful in identifying early or recurrent signs or symptoms and in involving the patient in treatment.

#### PRIMARY CLINICAL COMPONENT

Bipolar disorder; assessment for change in symptom complex

#### **DENOMINATOR DESCRIPTION**

Patients diagnosed and treated for bipolar disorder (see the related "Denominator Inclusions/Exclusions" field in the Complete Summary)

#### **NUMERATOR DESCRIPTION**

Patients who were assessed for change in their symptom complex, using a validated tool or a monitoring form, within 12 weeks of initiating treatment for bipolar disorder (see the related "Numerator Inclusions/Exclusions" field in the Complete Summary)

## **Evidence Supporting the Measure**

#### **EVIDENCE SUPPORTING THE CRITERION OF QUALITY**

- A clinical practice guideline or other peer-reviewed synthesis of the clinical evidence
- A formal consensus procedure involving experts in relevant clinical, methodological, and organizational sciences
- One or more research studies published in a National Library of Medicine (NLM) indexed, peer-reviewed journal

# **Evidence Supporting Need for the Measure**

## **NEED FOR THE MEASURE**

Unspecified

# **State of Use of the Measure**

#### **STATE OF USE**

Current routine use

#### **CURRENT USE**

Internal quality improvement

# **Application of Measure in its Current Use**

#### **CARE SETTING**

Ambulatory Care Behavioral Health Care Physician Group Practices/Clinics

#### PROFESSIONALS RESPONSIBLE FOR HEALTH CARE

Advanced Practice Nurses Physicians Psychologists/Non-physician Behavioral Health Clinicians

## LOWEST LEVEL OF HEALTH CARE DELIVERY ADDRESSED

Individual Clinicians

# **TARGET POPULATION AGE**

Age greater than or equal to 18 years

#### **TARGET POPULATION GENDER**

Either male or female

## STRATIFICATION BY VULNERABLE POPULATIONS

Unspecified

# **Characteristics of the Primary Clinical Component**

# INCIDENCE/PREVALENCE

Unspecified

#### **ASSOCIATION WITH VULNERABLE POPULATIONS**

Unspecified

#### **BURDEN OF ILLNESS**

Unspecified

#### **UTILIZATION**

Unspecified

#### **COSTS**

Unspecified

**Institute of Medicine National Healthcare Quality Report Categories** 

## **IOM CARE NEED**

Getting Better Living with Illness

## **IOM DOMAIN**

Effectiveness

# **Data Collection for the Measure**

# **CASE FINDING**

Users of care only

# **DESCRIPTION OF CASE FINDING**

Patients with a diagnosis involving bipolar disorder: International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) or Diagnostic and Statistical Manual of Mental Disorders, Fourth Revision, Text Revision (DSM-IV-TR): 296.0x; 296.1x; 296.4x; 296.5x; 296.6x; 296.7; 296.80-82; 296.89; or 301.13

#### **DENOMINATOR SAMPLING FRAME**

Patients associated with provider

# **DENOMINATOR INCLUSIONS/EXCLUSIONS**

#### **Inclusions**

Patients 18 years of age or older with an initial diagnosis or new episode/presentation of bipolar disorder

#### AND

Documentation of a diagnosis of bipolar disorder; to include at least one of the following:

- Codes 296.0x; 296.1x; 296.4x; 296.5x; 296.6x; 296.7; 296.80; 296.81; 296.82; 296.89; 301.13 documented in body of chart, such as a pre-printed form completed by a clinician and/or codes documented in chart notes/forms
- Diagnosis or impression documented in chart indicating bipolar disorder
- Use of a screening/assessment tool for bipolar disorder with a score or conclusion that patient has bipolar disorder and indication that this information is used to establish or substantiate the diagnosis

#### **AND**

Documentation of treatment for bipolar disorder with relevant pharmacotherapy; a mood stabilizing agent and/or an antipsychotic agent

#### **Exclusions**

Unspecified

#### RELATIONSHIP OF DENOMINATOR TO NUMERATOR

All cases in the denominator are equally eligible to appear in the numerator

# **DENOMINATOR (INDEX) EVENT**

Clinical Condition Encounter Therapeutic Intervention

#### **DENOMINATOR TIME WINDOW**

Time window is a single point in time

#### **NUMERATOR INCLUSIONS/EXCLUSIONS**

## **Inclusions**

Symptom monitoring documentation must include the following:

• Assessment of the patient's symptom complex; to include at least three symptoms involved with a bipolar disorder episode

- Assessment of any change (indication of difference; better, worse, same, etc.) in the symptoms in response to treatment
- Use of a symptom monitoring tool\* or a symptom monitoring flow sheet that supports assessment of change-over-time

#### AND

#### Timeframe:

Monitoring of change in symptom complex requires an initial assessment and at least one follow-up assessment within the first 12 weeks following start of treatment for bipolar disorder.

#### \*Note:

- Altman Self Rating Scale for Mania: Clinician scored instrument
- Self Report Form for Mood Episodes: "Waiting Room" self-report tool, includes symptoms
- Symptom Monitoring Flow Chart: Brief documentation tool for office-based practice

#### **Exclusions**

Unspecified

# MEASURE RESULTS UNDER CONTROL OF HEALTH CARE PROFESSIONALS, ORGANIZATIONS AND/OR POLICYMAKERS

The measure results are somewhat or substantially under the control of the health care professionals, organizations and/or policymakers to whom the measure applies.

#### **NUMERATOR TIME WINDOW**

Encounter or point in time

### **DATA SOURCE**

Administrative data Medical record

## LEVEL OF DETERMINATION OF QUALITY

Individual Case

## **PRE-EXISTING INSTRUMENT USED**

- Altman Self Rating Scale for Mania: Clinician scored instrument (available at www.cgaimh.org/stable.html)
- Self Report Form for Mood Episodes: "Waiting Room" self-report tool, includes symptoms (available at <a href="https://www.cqaimh.org/stable.html">www.cqaimh.org/stable.html</a>)
- Symptom Monitoring Flow Chart: Brief documentation tool for office-based practice (available at <a href="https://www.cqaimh.org/stable.html">www.cqaimh.org/stable.html</a>)

## **Computation of the Measure**

## **SCORING**

Rate

#### **INTERPRETATION OF SCORE**

Better quality is associated with a higher score

#### ALLOWANCE FOR PATIENT FACTORS

Unspecified

## STANDARD OF COMPARISON

Internal time comparison

# **Evaluation of Measure Properties**

#### **EXTENT OF MEASURE TESTING**

- The STABLE measures were developed using the RAND Appropriateness Method and have been shown to have content validity and face validity.
- Data feasibility testing was performed to determine the availability of the data elements required in the measure numerator and denominator specifications.
- Inter-abstractor reliability testing was performed to assess the data collection strategy. The data collection strategy included data collection forms; data dictionary references and abstractor instructions.
- A field study was conducted to determine measure conformance in an appropriate convenience sample.

Refer to the references listed below for further information.

#### **EVIDENCE FOR RELIABILITY/VALIDITY TESTING**

STABLE performance measures: data feasibility testing & results. Boston (MA): Center for Quality Assessment and Improvement in Mental Health; 2007. 2 p.

STABLE performance measures: development process & validity ratings. Boston (MA): Center for Quality Assessment and Improvement in Mental Health; 2007. 3 p.

STABLE performance measures: field study process & conformance findings. Boston (MA): Center for Quality Assessment and Improvement in Mental Health; 2007. 3 p.

STABLE performance measures: inter-abstractor reliability testing & results. Boston (MA): Center for Quality Assessment and Improvement in Mental Health; 2007. 2 p.

# **Identifying Information**

#### **ORIGINAL TITLE**

Bipolar disorder: monitoring change in symptom complex.

#### **MEASURE COLLECTION**

Standards for Bipolar Excellence (STABLE) Performance Measures

#### **SUBMITTER**

Center for Quality Assessment and Improvement in Mental Health

#### **DEVELOPER**

STABLE Project National Coordinating Council

## **FUNDING SOURCE(S)**

AstraZeneca LLP, Wilmington, Delaware, provided financial sponsorship for the STABLE Project. They did not otherwise participate in the development of either the measures or toolkit.

#### **COMPOSITION OF THE GROUP THAT DEVELOPED THE MEASURE**

The STABLE <u>National Coordinating Council (NCC)</u> was comprised of national experts in bipolar disorder, psychiatry, primary care, and performance improvement. The NCC guided and directed the STABLE Project. NCC members agreed to serve with the understanding that the STABLE Performance Measures and Resource Toolkit would be fully transparent and available without cost in the public domain.

<u>EPI-Q, Inc.</u>, is a consulting company providing practice-based outcomes research, pharmacoeconomic studies, and quality improvement services. EPI-Q managed the STABLE Project.

## FINANCIAL DISCLOSURES/OTHER POTENTIAL CONFLICTS OF INTEREST

Unspecified

# **ADAPTATION**

Measure was not adapted from another source.

#### **RELEASE DATE**

2007 Jan

#### **MEASURE STATUS**

This is the current release of the measure.

## SOURCE(S)

STABLE (STAndards for BipoLar Excellence) performance measures. Boston (MA): Center for Quality Assessment and Improvement in Mental Health; 2007. various p.

#### **MEASURE AVAILABILITY**

The individual measure, "Bipolar Disorder: Monitoring Change in Symptom Complex," is published in "STABLE (STAndards for BipoLar Excellence)
Performance Measures." This document is available in Portable Document Format (PDF) from the Center for Quality Assessment and Improvement in Mental Health (CQAIMH) Web site.

### **COMPANION DOCUMENTS**

The following is available:

• STABLE National Coordinating Council Resource Toolkit Workgroup. STABLE resource toolkit. Boston (MA): Center for Quality Assessment and Improvement in Mental Health; 2007 Mar. 67 p. This document is available in Portable Document Format (PDF) from the Center for Quality Assessment and Improvement in Mental Health (CQAIMH) Web site.

# **NQMC STATUS**

This NQMC summary was completed by ECRI Institute on January 10, 2008. The information was verified by the measure developer on April 14, 2008.

#### **COPYRIGHT STATEMENT**

The STABLE materials published on this Web site are copyrighted by CQAIMH. They may be used for research, teaching, and quality measurement/improvement activities – provided the following:

- The materials are not sold, distributed or licensed for commercial purposes.
- COAIMH's copyright is acknowledged in reproductions of these materials.
- Modifications to the materials are not made without CQAIMH's permission.

#### Disclaimer

The National Quality Measures Clearinghouse™ (NQMC) does not develop, produce, approve, or endorse the measures represented on this site.

All measures summarized by NQMC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public and private organizations, other government agencies, health care organizations or plans, individuals, and similar entities.

Measures represented on the NQMC Web site are submitted by measure developers, and are screened solely to determine that they meet the NQMC Inclusion Criteria which may be found at

http://www.gualitymeasures.ahrg.gov/about/inclusion.aspx.

NQMC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or its reliability and/or validity of the quality measures and related materials represented on this site. The inclusion or hosting of measures in NQMC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding measure content are directed to contact the measure developer.

© 2008 National Quality Measures Clearinghouse

Date Modified: 11/3/2008

